Clinical Outcomes in Metabolically Healthy and Unhealthy Obese and Overweight Patients With Atrial Fibrillation: Findings From the GLORIA-AF Registry

被引:10
|
作者
Corica, Bernadette [1 ,2 ,3 ]
Romiti, Giulio Francesco [1 ,2 ,3 ]
Proietti, Marco [1 ,2 ,4 ,5 ]
Mei, Davide Antonio [1 ,2 ,6 ]
Boriani, Giuseppe [6 ]
Chao, Tze-Fan [7 ,8 ,9 ]
Olshansky, Brian [10 ]
V. Huisman, Menno [11 ]
Lip, Gregory Y. H. [12 ,13 ]
机构
[1] Univ Liverpool, Liverpool John Moores Univ, Liverpool Ctr Cardiovasc Sci, Liverpool, England
[2] Liverpool Heart & Chest Hosp, Liverpool, England
[3] Sapienza Univ Rome, Dept Translat & Precis Med, Rome, Italy
[4] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy
[5] IRCCS Ist Clin Sci Maugeri, Geriatr Unit, Milan, Italy
[6] Univ Modena & Reggio Emilia, Cardiol Div, Dept Biomed Metab & Neural Sci, Policlin Modena, Modena, Italy
[7] Taipei Vet Gen Hosp, Dept Med, Div Cardiol, Taipei, Taiwan
[8] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Taipei, Taiwan
[9] Natl Yang Ming Chiao Tung Univ, Cardiovasc Res Ctr, Taipei, Taiwan
[10] Univ Iowa Hosp & Clin, Dept Internal Med, Div Cardiol, Iowa City, IA USA
[11] Leiden Univ, Med Ctr, Dept Thrombosis & Hemostasis, Leiden, Netherlands
[12] Aalborg Univ, Danish Ctr Hlth Serv Res, Dept Clin Med, Aalborg, Denmark
[13] Univ Liverpool, Liverpool Ctr Cardiovasc Sci, William Henry Duncan Bldg,6 W Derby St, Liverpool L7 8TX, England
关键词
BODY-MASS INDEX; WEIGHT; MANAGEMENT; RISK; ASSOCIATION; PREVENTION; REDUCTION; MORTALITY; PARADOX; DISEASE;
D O I
10.1016/j.mayocp.2023.07.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To explore the association between metabolic status, body mass index (BMI), and natural history of patients with atrial fibrillation (AF). Methods: The global, prospective GLORIA-AF Registry Phase II and III included patients with recent diagnosis of AF between November 2011 and December 2014 for Phase II and between January 2014 and December 2016 for Phase III. With this analysis, we categorized patients with AF according to BMI (normal weight [18.5 to 24.9 kg/m2], overweight [25.0 to 29.9 kg/m2], obese [30.0 to 60.0 kg/m2]) and metabolic status (presence of hypertension, diabetes, and hyperlipidemia). We analyzed risk of major outcomes using multivariable Cox regression analyses; the primary outcome was the composite of all-cause death and major adverse cardiovascular events. Results: There were 24,828 (mean age, 70.1 +/- 10.3 years; 44.6% female) patients with AF included. Higher BMI was associated with metabolically unhealthy status and higher odds of receiving oral anticoagulants and other treatments. Normal-weight unhealthy patients showed a higher risk of the primary composite outcome (adjusted hazard ratio [aHR], 1.20; 95% CI, 1.01 to 1.42) and thromboembolism, whereas a lower risk of cardiovascular death (aHR, 0.35; 95% CI, 0.14 to 0.88) and major adverse cardiovascular events (aHR, 0.56; 95% CI, 0.33 to 0.93) was observed in metabolically healthy obese individuals. Unhealthy metabolic groups were also associated with increased risk of major bleeding (aHR, 1.51 [95% CI, 1.04 to 2.20] and aHR, 1.96 [95% CI, 1.34 to 2.85] in overweight and Conclusion: Increasing BMI was associated with poor metabolic status and with more intensive treatment. Prognosis was heterogeneous between BMI groups, with metabolically unhealthy patients showing higher risk of adverse events. (c) 2023 THE AUTHORS. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research. This is an open access article under
引用
收藏
页码:927 / 939
页数:13
相关论文
共 50 条
  • [41] Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
    Lip, Gregory Y. H.
    Kotalczyk, Agnieszka
    Teutsch, Christine
    Diener, Hans-Christoph
    Dubner, Sergio J.
    Halperin, Jonathan L.
    Ma, Chang-Sheng
    Rothman, Kenneth J.
    Marler, Sabrina
    Gurusamy, Venkatesh Kumar
    Huisman, Menno, V
    CLINICAL RESEARCH IN CARDIOLOGY, 2022, 111 (05) : 560 - 573
  • [42] A PROSPECTIVE GLOBAL REGISTRY ON ORAL ANTITHROMBOTIC TREATMENT IN PATIENTS WITH ATRIAL FIBRILLATION: GLORIA-AF PHASE III BASELINE CHARACTERISTICS
    Huisman, M.
    Diener, H.
    Dubner, S.
    Halperin, J.
    Rothman, K.
    Ma, C.
    Lu, S.
    Paquette, M.
    Teutsch, C.
    Franca, L.
    Zint, K.
    Lip, G.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2019, 21 (0E) : E113 - E113
  • [43] Implications of Clinical Risk Phenotypes on the Management and Natural History of Atrial Fibrillation: A Report From the GLORIA-AF
    Romiti, Giulio Francesco
    Proietti, Marco
    Corica, Bernadette
    Bonini, Niccolo
    Boriani, Giuseppe
    Huisman, Menno V.
    Lip, Gregory Y. H.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (20):
  • [44] A prospective global registry on oral antithrombotic treatment in patients with atrial fibrillation: GLORIA-AF Phase III baseline characteristics
    Huisman, M. V.
    Diener, H. -C.
    Dubner, S. J.
    Halperin, J. L.
    Rothman, K. J.
    Ma, C. -S.
    Lu, S.
    Paquette, M.
    Teutsch, C.
    Franca, L. R.
    Zint, K.
    Lip, G. Y. H.
    EUROPEAN HEART JOURNAL, 2018, 39 : 825 - 825
  • [45] Characteristics and 2-year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA-AF
    Dubner, Sergio J.
    Teutsch, Christine
    Huisman, Menno V.
    Diener, Hans-Christoph
    Halperin, Jonathan
    Rothman, Kenneth J.
    Ma, Chang-Sheng
    Chuquiure-Valenzuela, Eduardo
    Bergler-Klein, Jutta
    Zint, Kristina
    Riou Franca, Lionel
    Lu, Shihai
    Paquette, Miney
    Lip, Gregory Y. H.
    ESC HEART FAILURE, 2020, 7 (05): : 2679 - 2689
  • [46] Two-year outcomes of dabigatran etexilate treatment in patients with co-morbid heart failure and atrial fibrillation: the GLORIA-AF registry
    Dubner, S. J.
    Huisman, M. V.
    Diener, H. C.
    Halperin, J. L.
    Rothman, K. J.
    Ma, C. S.
    Bergler-Klein, J.
    Zint, K.
    Franca, L. Riou
    Lu, S.
    Teutsch, C.
    Paquette, M.
    Lip, G. Y. H.
    EUROPEAN HEART JOURNAL, 2018, 39 : 606 - 607
  • [47] Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme
    Mazurek, Michal
    Halperin, Jonathan L.
    Huisman, Menno V.
    Diener, Hans-Christoph
    Dubner, Sergio J.
    Ma, Chang Sheng
    Rothman, Kenneth J.
    Healey, Jeff S.
    Teutsch, Christine
    Paquette, Miney
    Franca, Lionel Riou
    Lu, Shihai
    Bartels, Dorothee B.
    Lip, Gregory Y. H.
    EUROPACE, 2020, 22 (01): : 47 - 57
  • [48] Effectiveness and safety of dabigatran in Latin American patients with atrial fibrillation: Two years follow up results from GLORIA-AF registry
    Dubner, Sergio
    Saraiva, Jose Francisco Kerr
    Nunez Fragoso, Juan Carlos
    Baron-Esquivias, Gonzalo
    Teutsch, Christine
    Gurusamy, Venkatesh Kumar
    Marler, Sabrina
    Huisman, Menno, V
    Lip, Gregory Y. H.
    Zeballos, Cecilia
    IJC HEART & VASCULATURE, 2020, 31
  • [49] Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
    Gregory Y. H. Lip
    Agnieszka Kotalczyk
    Christine Teutsch
    Hans-Christoph Diener
    Sergio J. Dubner
    Jonathan L. Halperin
    Chang-Sheng Ma
    Kenneth J. Rothman
    Sabrina Marler
    Venkatesh Kumar Gurusamy
    Menno V. Huisman
    Clinical Research in Cardiology, 2022, 111 : 593 - 593
  • [50] Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry
    Ntaios, George
    Huisman, Menno, V
    Diener, Hans-Christoph
    Halperin, Jonathan L.
    Teutsch, Christine
    Marler, Sabrina
    Gurusamy, Venkatesh K.
    Thompson, Milla
    Lip, Gregory Y. H.
    Olshansky, Brian
    HELLENIC JOURNAL OF CARDIOLOGY, 2021, 62 (02) : 152 - 157